Pharmacology of metabotropic glutamate receptor allosteric modulators: Structural basis and therapeutic potential for CNS disorders

Karen Joan Gregory, Meredith J Noetzel, Colleen M Niswender

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

The metabotropic glutamate receptors (mGlus) mediate a neuromodulatory role throughout the brain for the major excitatory neurotransmitter, glutamate. Seven of the eight mGlu subtypes are expressed within the CNS and are attractive targets for a variety of psychiatric and neurological disorders including anxiety, depression, schizophrenia, Parkinson s disease, and Fragile X syndrome. Allosteric modulation of these class C 7-transmembrane spanning receptors represents a novel approach to facilitate development of mGlu subtype-selective probes and therapeutics. Allosteric modulators that interact with sites topographically distinct from the endogenous ligand-binding site offer a number of advantages over their competitive counterparts. In particular for CNS therapeutics, allosteric modulators have the potential to maintain the spatial and temporal aspects of endogenous neurotransmission. The past 15 years have seen the discovery of numerous subtype-selective allosteric modulators for the majority of the mGlu family members, including positive, negative, and neutral allosteric modulators, with a number of mGlu allosteric modulators now in clinical trials.
Original languageEnglish
Title of host publicationProgress in Molecular Biology and Translational Science
EditorsTerry Kenakin
Place of PublicationOxford UK
PublisherElsevier
Pages61 - 121
Number of pages61
ISBN (Print)978-0-12-394587-7
DOIs
Publication statusPublished - 2013

Cite this

Gregory, K. J., Noetzel, M. J., & Niswender, C. M. (2013). Pharmacology of metabotropic glutamate receptor allosteric modulators: Structural basis and therapeutic potential for CNS disorders. In T. Kenakin (Ed.), Progress in Molecular Biology and Translational Science (pp. 61 - 121). Oxford UK: Elsevier. https://doi.org/10.1016/B978-0-12-394587-7.00002-6
Gregory, Karen Joan ; Noetzel, Meredith J ; Niswender, Colleen M. / Pharmacology of metabotropic glutamate receptor allosteric modulators: Structural basis and therapeutic potential for CNS disorders. Progress in Molecular Biology and Translational Science. editor / Terry Kenakin. Oxford UK : Elsevier, 2013. pp. 61 - 121
@inbook{ea873115077a4762a5da284d6489f049,
title = "Pharmacology of metabotropic glutamate receptor allosteric modulators: Structural basis and therapeutic potential for CNS disorders",
abstract = "The metabotropic glutamate receptors (mGlus) mediate a neuromodulatory role throughout the brain for the major excitatory neurotransmitter, glutamate. Seven of the eight mGlu subtypes are expressed within the CNS and are attractive targets for a variety of psychiatric and neurological disorders including anxiety, depression, schizophrenia, Parkinson s disease, and Fragile X syndrome. Allosteric modulation of these class C 7-transmembrane spanning receptors represents a novel approach to facilitate development of mGlu subtype-selective probes and therapeutics. Allosteric modulators that interact with sites topographically distinct from the endogenous ligand-binding site offer a number of advantages over their competitive counterparts. In particular for CNS therapeutics, allosteric modulators have the potential to maintain the spatial and temporal aspects of endogenous neurotransmission. The past 15 years have seen the discovery of numerous subtype-selective allosteric modulators for the majority of the mGlu family members, including positive, negative, and neutral allosteric modulators, with a number of mGlu allosteric modulators now in clinical trials.",
author = "Gregory, {Karen Joan} and Noetzel, {Meredith J} and Niswender, {Colleen M}",
year = "2013",
doi = "10.1016/B978-0-12-394587-7.00002-6",
language = "English",
isbn = "978-0-12-394587-7",
pages = "61 -- 121",
editor = "Terry Kenakin",
booktitle = "Progress in Molecular Biology and Translational Science",
publisher = "Elsevier",
address = "Netherlands",

}

Gregory, KJ, Noetzel, MJ & Niswender, CM 2013, Pharmacology of metabotropic glutamate receptor allosteric modulators: Structural basis and therapeutic potential for CNS disorders. in T Kenakin (ed.), Progress in Molecular Biology and Translational Science. Elsevier, Oxford UK, pp. 61 - 121. https://doi.org/10.1016/B978-0-12-394587-7.00002-6

Pharmacology of metabotropic glutamate receptor allosteric modulators: Structural basis and therapeutic potential for CNS disorders. / Gregory, Karen Joan; Noetzel, Meredith J; Niswender, Colleen M.

Progress in Molecular Biology and Translational Science. ed. / Terry Kenakin. Oxford UK : Elsevier, 2013. p. 61 - 121.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - Pharmacology of metabotropic glutamate receptor allosteric modulators: Structural basis and therapeutic potential for CNS disorders

AU - Gregory, Karen Joan

AU - Noetzel, Meredith J

AU - Niswender, Colleen M

PY - 2013

Y1 - 2013

N2 - The metabotropic glutamate receptors (mGlus) mediate a neuromodulatory role throughout the brain for the major excitatory neurotransmitter, glutamate. Seven of the eight mGlu subtypes are expressed within the CNS and are attractive targets for a variety of psychiatric and neurological disorders including anxiety, depression, schizophrenia, Parkinson s disease, and Fragile X syndrome. Allosteric modulation of these class C 7-transmembrane spanning receptors represents a novel approach to facilitate development of mGlu subtype-selective probes and therapeutics. Allosteric modulators that interact with sites topographically distinct from the endogenous ligand-binding site offer a number of advantages over their competitive counterparts. In particular for CNS therapeutics, allosteric modulators have the potential to maintain the spatial and temporal aspects of endogenous neurotransmission. The past 15 years have seen the discovery of numerous subtype-selective allosteric modulators for the majority of the mGlu family members, including positive, negative, and neutral allosteric modulators, with a number of mGlu allosteric modulators now in clinical trials.

AB - The metabotropic glutamate receptors (mGlus) mediate a neuromodulatory role throughout the brain for the major excitatory neurotransmitter, glutamate. Seven of the eight mGlu subtypes are expressed within the CNS and are attractive targets for a variety of psychiatric and neurological disorders including anxiety, depression, schizophrenia, Parkinson s disease, and Fragile X syndrome. Allosteric modulation of these class C 7-transmembrane spanning receptors represents a novel approach to facilitate development of mGlu subtype-selective probes and therapeutics. Allosteric modulators that interact with sites topographically distinct from the endogenous ligand-binding site offer a number of advantages over their competitive counterparts. In particular for CNS therapeutics, allosteric modulators have the potential to maintain the spatial and temporal aspects of endogenous neurotransmission. The past 15 years have seen the discovery of numerous subtype-selective allosteric modulators for the majority of the mGlu family members, including positive, negative, and neutral allosteric modulators, with a number of mGlu allosteric modulators now in clinical trials.

UR - http://www.sciencedirect.com/science/article/pii/B9780123945877000026

U2 - 10.1016/B978-0-12-394587-7.00002-6

DO - 10.1016/B978-0-12-394587-7.00002-6

M3 - Chapter (Book)

SN - 978-0-12-394587-7

SP - 61

EP - 121

BT - Progress in Molecular Biology and Translational Science

A2 - Kenakin, Terry

PB - Elsevier

CY - Oxford UK

ER -

Gregory KJ, Noetzel MJ, Niswender CM. Pharmacology of metabotropic glutamate receptor allosteric modulators: Structural basis and therapeutic potential for CNS disorders. In Kenakin T, editor, Progress in Molecular Biology and Translational Science. Oxford UK: Elsevier. 2013. p. 61 - 121 https://doi.org/10.1016/B978-0-12-394587-7.00002-6